Default company panoramic image
Logo

SpineThera

Better drugs for back pain to improve treatment outcomes, lower patient risk, and reduce treatment costs.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Plymouth, MN, US
  • Currency USD
  • Founded September 2011
  • Employees 4
  • Incorporation Type C-corp
  • Website spinethera.com

Company Summary

SpineThera’s lead product candidate (SX600) is a long-acting, injectable corticosteroid micro-suspension targeted to reduce the number and frequency of epidural steroid injections for lumbosacral radiculopathy, a common form of back pain.

Team

  • Jeff has an extensive background in formulation, preclinical, and clinical development of polymeric, sustained release drug products. He led the formulation development and clinical study manufacturing of a sustained release steroid implant for ocular administration that was licensed to Merck for $40M.
    PLEASE VISIT WEBSITE FOR COMPLETE TEAM PROFILES